For research use only. Not for therapeutic Use.
CIQ is a subunit-selective potentiator of NMDA receptors containing the NR2C or NR2D subunit.
IC50 value: 2.7 μM (EC50, for NR2C) and 2.8 μM (EC50, NR2D)
Target: NMDA receptor
CIQ increases channel opening frequency of recombinant NR2Cor NR2D containing receptors by two-fold (EC50 = 2.7 and 2.8 μM, respectively), with no effect on NR2A or NR2B subtypes. CIQ does not alter the EC50 values for glutamate or glycine on channel opening. CIQ increases channel opening efficiency and enhances NMDA receptor responses. CIQ reduces associated behaviours in schizophrenia models and potentially enhances dopamine release in Parkinson’s disease models.
| Catalog Number | I003711 |
| CAS Number | 486427-17-2 |
| Synonyms | (3-chlorophenyl)-[6,7-dimethoxy-1-[(4-methoxyphenoxy)methyl]-3,4-dihydro-1H-isoquinolin-2-yl]methanone |
| Molecular Formula | C26H26ClNO5 |
| Purity | ≥95% |
| InChI | InChI=1S/C26H26ClNO5/c1-30-20-7-9-21(10-8-20)33-16-23-22-15-25(32-3)24(31-2)14-17(22)11-12-28(23)26(29)18-5-4-6-19(27)13-18/h4-10,13-15,23H,11-12,16H2,1-3H3 |
| InChIKey | VYMILMYEENZHAR-UHFFFAOYSA-N |
| SMILES | COC1=CC=C(C=C1)OCC2C3=CC(=C(C=C3CCN2C(=O)C4=CC(=CC=C4)Cl)OC)OC |
